Introduction
Primary mitochondrial diseases encompass a wide range of heritable conditions having greatly variable age of onset across the lifespan, clinical and biochemical manifestations, and molecular etiologies [1•] . Collectively, they affect at least 1 in 4300 individuals across all ages [2] . As understanding of mitochondrial pathophysiology has expanded over the past three decades so, too, has clinical care standards [3•] and the development of precision therapies that are aimed at targeting the precise pathophysiology of the underlying gene defect [4•] . This review highlights the historical context and impact of recent rapid advancements made in diagnosing and treating mitochondrial disease.
Mitochondrial Disease Overview
Mitochondrial disease manifestations are notoriously heterogeneous, with involvement of potentially any organ system at any age. Clinical manifestations may range from isolated organ involvement with onset late in life to onset of severe multi-system problems in the newborn period leading to early death. Single-organ symptoms may be the cardinal or only symptom, but more commonly progressive problems develop over time in additional systems. Disease courses may be characterized by rapid decline or prolonged periods of stability with intercurrent decompensation with stressors such as infections, fevers, or anesthesia. Symptom severity may range from mild to severe, and fluctuate over time. Multi-system manifestations, particularly when progressive over time, should prompt consideration of primary mitochondrial disease, especially when involving functional rather than structural manifestations. Dysmorphic features are recognized in some primary mitochondrial diseases, but remain relatively uncommon, as are rheumatologic, dermatologic, oncologic, and primary orthopedic problems.
While isolated organ involvement can be seen in primary mitochondrial disease, it is increasingly recognized that this may represent the mild end of the pleiotropic disease spectrum with more "plus" multi-system phenotypes often recognized when careful clinical evaluation is performed. This is exemplified by OPA1 disorders, primarily recognized for causing isolated optic neuropathy in an autosomal dominant fashion [5] but now recognized to variably cause a range of additional features including hearing loss, ataxia, and peripheral neuropathy [6] . Similarly, while Leber's hereditary optic neuropathy (LHON) that results from pathogenic mtDNA mutations in complex I subunit genes is still largely considered to be an isolated optic neuropathy onset in early adulthood, individuals can manifest in mid-childhood and additional features including neurologic problems, cardiomyopathy, and arrhythmia can occur [7, 8] . In addition, adult-onset progressive external ophthalmoplegia (PEO) that is characterized primarily as an eye movement disorder with ptosis is often identified as PEOplus, with additional multi-system involvement such as exercise intolerance and myopathy [9] [10] [11] . The increased recognition of a broader spectrum of manifestations beyond classically defined clinical syndromes is reflected in updated expert consensus-based clinical care management guidelines [3•] .
Childhood-onset primary mitochondrial disease is more commonly caused by nuclear DNA pathogenic mutations (typically recessive but also X-linked can be seen), although improvements in mtDNA whole genome sequencing sensitivity has enabled recognition of a growing number of earlyonset mtDNA disorders. Conversely, while adult-onset mitochondrial disease is more commonly caused by pathogenic mtDNA variants, improved genomic sequencing technologies has led to a growing number of adult-onset nuclear gene etiologies. In general, mtDNA heteroplasmy levels that are causal of childhood-onset severe phenotypes are typically higher than levels seen in adult-onset clinical diseases, including within members of a given family.
Neurologic Manifestations
While none are pathognomonic, several neurologic "red flag" manifestations raise high concern for primary mitochondrial disease including Leigh syndrome (bilateral symmetric necrotic lesions in the basal ganglia, brainstem, and midbrain that may fluctuate over time and present as hyperintense lesions on brain magnetic resonance imaging) that is now recognized to result from mutations in more than 75 distinct genes across both genomes [12, 13] . Other common neurologic manifestations include epilepsia partialis continua (EPC) [14, 15] , occipital stroke-like episodes and strokes that do not follow a vascular distribution, and axonal sensorimotor neuropathy. Other common neurologic features include myoclonus, ataxia, a range of other seizure types, movement disorders, and developmental regression. While neurodevelopmental features such as autism, developmental regression, and intellectual disability can certainly be seen in those with primary mitochondrial disease, it is rare that these would be the only manifestation of a primary mitochondrial disease [16] .
Ophthalmologic Manifestations
Ophthalmic features of mitochondrial disease commonly include PEO, ptosis, pigmentary retinal dystrophy, and optic atrophy that can reduce visual acuity and be progressive over time [17] . In fact, over time, 81% of pediatric and young adult mitochondrial disease patients may develop significant eye problems [18] .
Audiologic Manifestations
Hearing loss in primary mitochondrial disease is typically bilateral, high frequency, sensorineural hearing loss that can range from mild to profound with variable age of onset.
Specific pathogenic mtDNA mutations, particularly in MT-RNR1 and MT-TS1, have been found to cause isolated hearing loss. The m.1555A > G mutation in MT-RNR1 has been associated with hearing loss, occurring both acutely following exposure to an aminoglycoside antibiotic [19] [20] [21] and over time even in the absence of aminoglycoside exposure; and accounts for 5% of all cases of isolated sensorineural hearing loss [22] . Isolated sensorineural hearing loss has also been associated with several mtDNA variants in MT-TS1, with presentation typically in childhood [23] .
Cochlear implants have been shown to be an effective therapy for both syndromic and non-syndromic types of hearing loss in mitochondrial disease, with improvements seen both immediately following surgery and long-term [24] .
Cardiac Manifestations
Hypertrophic cardiomyopathy is the most common cardiac feature of primary mitochondrial disease, occurring in approximately 40% of affected individuals [25] [26] [27] [28] . Dilated cardiomyopathy is less common but does occur.
Arrhythmias are also seen in primary mitochondrial disease, and recently have been associated with sudden cardiac death in MELAS [29] . Common arrhythmias observed in patients with mitochondrial disease include Wolff-ParkinsonWhite and ventricular pre-excitation.
Cardiac conduction defects are also seen, most notably in mtDNA deletion disorders such as Kearns-Sayre syndrome.
As this can rapidly progress to high-grade AV block and sudden cardiac death, cardiac pacemaker and defibrillator are strongly recommended if symptoms or early conduction changes on electrocardiogram appear [3•, 30] .
Given the frequent incidence of cardiac defects in primary mitochondrial disease and the potential for life-saving interventions when cardiac problems are identified early, cardiac evaluation performed at least annually to include echocardiogram and electrocardiogram is recommended when an individual is suspected to have mitochondrial disease or is first diagnosed.
Cardiopulmonary exercise testing (CPET) is an increasingly useful tool to non-invasively evaluate mitochondrial disease severity, exercise capacity, and to monitor disease progression over time. Characteristic CPET findings in mitochondrial disease include reduced peak work rate and peak exercise oxygen delivery ('VO 2 max'), elevated respiratory exchange ratio, and early lactic acidosis threshold [31] [32] [33] .
Gastrointestinal Manifestations
Gastrointestinal manifestations of mitochondrial disease are common, disabling, and often untreated due to being poorly recognized by treating clinicians. Gastrointestinal symptoms are commonly characterized by dysmotility, including dysphagia, gastroesophageal reflux disease, delayed gastric emptying, constipation, pseudo-obstruction, and vomiting. Failure to thrive, malabsorption, and exocrine pancreatic insufficiency may occur. Irritable bowel syndrome or isolated diarrhea is less frequent. Liver involvement can also occur, including hepatic steatosis and mtDNA depletion, and in some cases may only occur when exacerbated by stressors such as dehydration or antiepileptic drugs (such as valproate) in POLGrelated mitochondrial disease.
Endocrine Manifestations
Diabetes mellitus is the most commonly seen endocrine manifestation of mitochondrial disease. It can be type I or type II, although combined insulin deficiency and resistance appears more common in patients with primary mitochondrial disease [34] [35] [36] [37] . Adrenal dysfunction, hypoparathyroidism, thyroid dysfunction, growth failure, and underweight or overweight are also common endocrine manifestations [34, 38] . Hypogonadism may occur in primary mitochondrial disease, including hypergonadotrophic or hypogonadotrophic hypogonadism. Infertility and premature ovarian failure may be a feature of some mitochondrial diseases such as POLG disease. Poor bone health has also been shown to occur in those with primary mitochondrial disease [39] .
Renal Manifestations
Kidney involvement has been seen in up to 25% of primary mitochondrial disease patients [40] . Renal manifestations may be characterized by impairment of either tubular (renal tubular acidosis, hypercalciuria with hyperuricosuria, hypouricemia, nephrocalcinosis, renal calculi) and/or glomerular (proteinuria, aminoaciduria, decreased GFR) function.
Clinical Diagnostic Approach
The evolving diagnostic approach to suspected primary mitochondrial disease has been expertly reviewed and summarized in several recent manuscripts by the Mitochondrial Medicine Society [41] [42] [43] . With the exception of molecular genetic diagnostic testing, diagnostic testing in blood, urine, and tissues largely evaluate for biochemical evidence of mitochondrial dysfunction. Detailing specific metabolite alterations and their association with mitochondrial dysfunction falls outside the scope of this current review, but has been reviewed previously [41] . Here, we outline a general diagnostic approach for suspected mitochondrial disease, an overview of which is provided in Fig. 1 .
Molecular Testing
The importance of identifying the underlying molecular etiology causing primary mitochondrial disease cannot be overstated. Not only is this needed to confirm that an individual has a primary mitochondrial disease, a molecular diagnosis is now also increasingly required for patients to participate in clinical treatment trials. Additionally, proper molecular diagnosis can lead to tailored treatments [4•] . Further, some conditions having considerable phenotypic overlap with mitochondrial disease, including biotin and thiamine responsive basal ganglia disease (SLC19A3 disease) and riboflavin transport deficiencies (SLC52A2 or SLC52A3 disease), are important to detect given the therapies that have been shown to improve clinical outcome.
While panel-based testing that includes sequencing of select nuclear genes and mtDNA can be helpful in those with multiple features highly concerning for classical mitochondrial disease syndromes, clinically based whole exome sequencing that includes mtDNA sequencing in both proband and parental samples is increasingly used as a first-line genetic test in both classical as well as more poorly-defined presentations. Mitochondrial disease-specific panel-based genetic testing would miss the treatable conditions having phenotypic overlap with primary mitochondrial disease, as well as secondary genetic disorders that may contribute to a complex phenotype and are now recognized to occur in 3 to 5% of individuals [44] . Limited gene panel-based diagnostic testing often does not include parental or family member samples, which are essential for segregation analysis and to identify de novo dominant mutations in the affected individual. Parental sequencing at the time of proband analysis provides crucial information to facilitate more rapid and accurate variant pathogenicity interpretation. Further, if this testing is not obtained at the time of the initial diagnostic test, it becomes exceedingly challenging to obtain insurance coverage for subsequent segregation analysis in healthy parents, even if it is needed to understand potential health risks to themselves and accurate disease diagnosis in their child.
Non-invasive Biochemical Screening Studies
Metabolic screening studies in blood and urine are useful to determine whether an individual with suspected primary mitochondrial disease has evidence for mitochondrial dysfunction. Caution must be used when interpreting these findings, as any alterations identified will not be specific to mitochondrial disease and are typically not diagnostic in isolation. Common tests used to screen for evidence of primary mitochondrial disease, other recognizable inborn errors of metabolism, or common secondary problems seen in mitochondrial disease include comprehensive chemistry panel, complete blood count with differential, blood lactate and pyruvate, ammonia, creatine kinase, hemoglobin A1C, plasma amino acid analysis, plasma carnitine and acylcarnitine profile, lipoprotein profile, hormone screening studies, and urine studies such as urinalysis, urine organic acid analysis, and urine amino acid analysis. Elevations of lactic acid and pyruvate are neither sensitive nor specific for all mitochondrial diseases, and may only be present intermittently in some individuals, but are important to recognize when present. To definitely confirm or exclude primary mitochondrial disease, additional diagnostic testing must be pursued beyond blood and urine based biochemical screens. Electron transport chain testing in buccal samples has become available in some centers, but has overall poor sensitivity and specificity for mitochondrial disease and not been proven to be highly reflective of ETC enzyme dysfunction in high-energy demand tissues [45] . Thus, additional research is needed before biochemical testing of ETC activity in buccal samples can be reliably used to aid in the diagnosis of primary mitochondrial disease.
High Index of Suspicion

Invasive Tissue Testing
For many years, skeletal muscle biopsy was considered the gold standard approach to diagnose primary mitochondrial disease. With the improved availability, turn-around-time, and diagnostic success of next-generation sequencing diagnostic methodologies, however, invasive tissue testing is less frequently pursued. Nonetheless, it may be useful following completion of genetic testing to better understand the degree of mitochondrial dysfunction or to confirm the presence of mitochondrial dysfunction in the event no clear molecular etiology is identified upon genetic testing of blood. Further, invasive testing may be crucial to obtain tissue in which to perform mtDNA content and mtDNA sequencing testing, since mtDNA depletion or mutations may only be detectable in symptomatic high-energy demand tissue, such as muscle or liver. ETC complexes I-IV enzyme activity analyses can be performed on a clinical diagnostic basis in muscle, skin, or liver samples, although complex V (ATP synthase) activity clinical analyses are not currently performed in the USA.
Mitochondrial Disease Therapies and a Look Toward the Future
Current Therapies
No cure or FDA-approved therapies currently exist for mitochondrial disease. However, increased understanding of the natural history of the various molecular subtypes of mitochondrial disease has allowed for more standardized screening evaluations and symptom-based management. Standard therapies are used to manage each underlying clinical manifestation identified, such as diabetes mellitus, adrenal insufficiency, thyroid hormone insufficiency, hearing loss, cardiac arrhythmias, and other disease-related symptoms. It is imperative that patients are routinely screened for the multitude of symptoms known for each condition, with appropriate multispecialist management provided. Detailed expert consensus guidelines were recently reported by the international members of the Mitochondrial Medicine Society (MMS) to standardize clinical care recommendations for various organ and disease symptoms [3•] .
Routine and Acute Clinical Management
Management of routine medical care to optimize health of mitochondrial disease patients is critical and includes obtaining recommended immunizations, avoiding fasting, minimizing febrile periods, achieving good sleep hygiene, and assuring proper nutrition. Treatment during acute illness, decompensation episodes, and other intercurrent stressors includes proper hydration and nutrition support, following recommended anesthetic guidelines, and closely following for new-onset neurologic disorders such as metabolic strokes or seizures. Extensive research has examined the use of intravenous arginine and citrulline as nitric oxide (NO) precursors in patients with classical MELAS [46, 47] . The recent expert consensus guidelines from the Mitochondrial Medicine Society recommend consideration for using intravenous arginine for acute stroke-like episodes in patients with the common mtDNA mutation in MELAS m.3243A > G in MT-TL1 [3•]. Recent retrospective analysis of intravenous arginine in other mitochondrial diseases with acute metabolic stroke risk further suggests consideration for using intravenous arginine at the time of acute metabolic stroke risk in non-MELAS patients in attempt to improved clinical outcomes and reduce residual deficits; more than 50% of pediatric mitochondrial disease patients who received intravenous arginine at the time of acute metabolic stroke-like episode in one center showed clinical response, particularly for hemiplegic symptoms, with no adverse events of the therapy observed [48] . Chronic administration of enteral arginine or citrulline therapy is an additional therapeutic strategy that may help prevent the occurrence of future metabolic strokes in at-risk mitochondrial disease patients [3•] .
Anesthesia is generally tolerated well in patients with mitochondrial disease. However, some patients, particularly those having complex I dysfunction, have been found to have volatile anesthetic hyper-sensitivity and subsequent adverse events such as respiratory depression, regression, and white matter changes [49] . Current clinical guidelines support a cautious approach to using anesthesia in patients with mitochondrial disease. Recommendations suggest avoiding or limiting propofol for short procedures (under 1 h in duration); limiting fasting and having glucose added to perioperative IV fluids to prevent catabolism, unless contraindicated; and slow titration of anesthetics to reduce hemodynamic changes [3•].
Exercise and Dietary Supplements
Exercise has been studied extensively and, when tolerated, is a proven therapy to improve the well-being of mitochondrial disease patients [50] . Aerobic and isotonic exercise has been shown to increase mitochondrial copy number, ETC enzyme activities, maximize mitochondrial oxygen uptake, and improve muscle strength. Consensus guidelines support the use of slowly accelerating exercise after patients are cleared by cardiac screening [3•, 43] . Patients should ideally maintain an exercise program to reduce their deconditioning under the supervision of a professional therapist or exercise physiologist. Maintaining a regular exercise regimen can provide improved quality of life for patients and increased independence for activities of daily living.
Dietary supplements have long been used in variable combinations and doses for mitochondrial disease. Understanding the broad pathophysiology of the underlying biochemical disorders has supported rationale for the empiric use of vitamin and cofactor supplements [51] . The most commonly used supplements include antioxidants (ubiquinol, α-lipoic acid, vitamins C and E), metabolites that increase free Coenzyme Q10 pools (carnitine), enzyme co-factors (B vitamins), and various metabolite therapies (arginine, folinic acid, creatine). While most appear to be well-tolerated overall, limited preclinical data exists and no robust clinical trials have determined the efficacy, potential toxicity, or optimal dose of any of these supplements in mitochondrial disease patients [52, 53] . These supplements are also typically given together in compounded formulations to ease patient adherence, which makes it difficult to determine which supplement is most advantageous alone, or whether synergistic effects result from specific treatment combinations. A survey of mitochondrial disease providers revealed extensive variability as to precisely which supplements were standardly recommend for mitochondrial disease patients [43] . Supplements are not subject to the regulatory framework required for medication quality and safety, may be high cost, and are not typically covered by insurance [54] . The current expert panel consensus guidelines from the Mitochondrial Medicine Society recommend the following supplements be offered to patient with mitochondrial disease: ubiquinol, α-lipoic acid, riboflavin, folinic acid in patients with neurological manifestations, and L-carnitine in patients with documented deficiency [43] . Creatine may also have utility in mitochondrial myopathy [51] .
Novel Therapies
Mitochondrial disease therapeutic development has been at the forefront of precision medicine. It is commonly recognized that successful improvement of health in individuals with primary mitochondrial disease might lead to effective therapies for more common and complex disorders whose pathogenesis involves secondary mitochondrial dysfunction, such as diabetes mellitus and neurodegenerative diseases of aging like Alzheimer's disease and Parkinson's disease.
A novel therapeutic approach being developed for some molecular subclasses of mitochondrial disease models is enzyme replacement therapy (ERT). Specifically, ERT has shown promising evidence in mitochondrial neurogastrointestinal encephalopathy (MNGIE) syndrome, where treatment in one patient involved erythrocyte-encapsulated thymidine phosphorylase, with additional study needed [55] . For mtDNA depletion disorders, a trial in thymidine kinase 2 (TK2) deficiency with combined nucleoside therapy, deoxynucleotide thymidine (dTMP) and cytidine monophosphates (dCMP), showed improvement in the neuromuscular manifestations of several patients [56] . Additional therapies are being investigated in research models to assess their ability to improve mitochondrial disease outcomes by modulating mitophagy, cellular translation, or hypoxia, as well as gene correction therapies using AAV vectors and mito-TALENS [57] [58] [59] [60] [61] . Further research is ongoing to translate these therapies from bench concepts to beside interventions aimed to improve the health of mitochondrial disease patients [62] .
Clinical Trials
Over the past 5 years, there has been initiation of multiple clinical trials in primary mitochondrial disease. Substantial hurdles remain, however, due to extensive variability in mitochondrial disease genetic etiologies, pathophysiology, symptoms, and clinical outcomes measures.
To address the underlying disease variability, small cohort and individualized ('n-of-1') trial designs may be appropriate. These allow for each patient to be compared to their own unique symptom constellation baseline rather than to that of all subjects enrolled with highly pleiotropic disorders. This model has been successful in ultrarare genetic disease and pediatric oncology trials [63] . The community has recognized the need for robust clinical trial design, including development and validation of mitochondrial disease-specific scales that can be standardized outcome measures across trials [52] . A recent example is the launch of a multi-center, randomized, placebo-controlled, crossover, double-blinded, phase III treatment trial to evaluate dichloroacetate in children with pyruvate dehydrogenase complex deficiency from multiple molecular causes, where the primary outcome measure is an observerreported daily electronic survey completed by parents to assess disease-related symptoms in patients [64] . While many trials are being planned as detailed in Table 1 , there has not been an FDA-approved pharmaceutical drug for mitochondrial disease. 
Mitochondrial Disease Recurrence Preventative Strategies
Reproductive options have long been available for families who have a confirmed nuclear gene cause for the mitochondrial disease in their family. Specific options vary from testing prior to pregnancy by pre-implantation genetic diagnosis (PGD) in the setting of in vitro fertilization (IVF), in which one or two cells from a day 3 or day 5 embryo are tested for the specific gene mutation that is known to cause disease in their family. Diagnostic options available during a pregnancy include mutation testing by chorionic villus sampling (CVS) at 10-12 weeks' gestation, or amniocentesis at 16-20 weeks' gestation [65] . For individuals with mtDNA disease that are complicated by heteroplasmy, reproductive options have been limited. Women who are asymptomatic and harbor a low level of mutation in their own blood may produce oocytes with high mutant loads that increase the risk their child will inherit high mutation levels and manifest severe disease [66] . Testing for heteroplasmic mtDNA disorders during a pregnancy can be both technically and clinically challenging, given the biological variability of mutation load in different tissues and inherent difficulty in accurately predicting clinical outcomes based on mtDNA mutation loads measured in amniotic fluid cells (that are fetal in origin) or chorionic villus cells (that derive from placenta). Recent research has improved understanding of the genetic bottleneck impact on mtDNA mutation inheritance [67] [68] [69] [70] , to establish clearer understanding of which mtDNA mutations may benefit from a PGD approach [71] . In the USA, PGD is allowable but may not be suitable or successful for individual mtDNA disease patients, and requires demonstrated diagnostic laboratory expertise in accurate single cell mtDNA mutation heteroplasmy analysis [72] . Modeling studies have suggested that embryo mutation loads below 5% (and possibly as high as 18%) are unlikely to become sufficiently enriched in the resulting organs of the child to manifest with clinical disease [73] . However, it may not be possible to identify a viable embryo that has sufficiently low mtDNA mutation heteroplasmy level to reduce the likelihood the resulting child will ultimately be affected with a severe mtDNA disease.
Mitochondrial replacement techniques (MRT) involve not just quantifying but first actively replacing the mother's mitochondria that contains mutant mitochondrial DNA in oocytes or zygotes with healthy mitochondria [74] . There are currently two methods by which MRT can be technically performed: metaphase spindle transfer and pronuclear transfer. Metaphase spindle transfer is performed in an oocyte prior to fertilization, replacing the maternal karyoplast with that of a donor oocyte but retaining the maternal nuclear genome with spindle chromosome complex [75] . Pronuclear transfer is conceptually similar but performed post-fertilization at the pronuclei stage of the early zygote [74, 76] . In either scenario, the intention is to generate an embryo to be selected for uterine implantation that has the intended parents' nuclear genetic material together with healthy mitochondria from an unrelated donor oocyte that harbors the lowest possible heteroplasmy level for the familial pathogenic mtDNA mutation. The mutant mtDNA heteroplasmy carry-over with MRT is typically not zero but based on research testing appears to be below 2%. Regardless, the inherently unpredictable nature of mtDNA replication warrants careful longterm follow-up in an experienced mitochondrial disease clinical center for any child born following PGD or MRT procedures in which detectable mtDNA mutation heteroplasmy level is confirmed.
The UK approved the pronuclear transfer technique for MRT under certain conditions in February 2015, which as of early 2018 is now proceeding with initial family selection to undergo this procedure [77] . Despite the National Academy of Medicine (now renamed Institute of Medicine) ethics panel review that suggested it is ethical under certain conditions to pursue MRT research for mitochondrial disease [78] , it remains illegal to implant an embryo generated by MRT due to a congressional ban on the Food and Drug Administration considering applications to perform these research trials. Careful attention will be focused on early MRT trial outcomes for mtDNA disease in the UK [79] . Transparent reporting of all long-term outcomes reported from women who undergo PGD or MRT will provide valuable information to assess the safety of offering these options to all women who harbor a pathogenic mtDNA mutation.
Conclusion
Understanding the clinical spectrum, diagnosis, management, and prevention of primary mitochondrial disease has markedly improved over the past three decades. Distinguishing the underlying genetic cause for complex clinical phenotypes affecting individual patients is increasingly feasible and necessary to enable development of precision therapies and disease prevention approaches. These advances are leading to improved clinical management options and emerging therapeutic trials for the highly heterogeneous group of complex, multi-system, energy deficienct primary mitochondrial diseases.
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